Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics reported significant financial growth for Q4 2022, with revenues increasing by 78% year-over-year to $181 million, driven by record royalty revenues of $106 million. Full-year revenues rose to $660.1 million, a 49% increase compared to 2021. GAAP diluted earnings per share for the fourth quarter were $0.42, while non-GAAP EPS was $0.48. For 2023, Halozyme expects revenues between $815 million and $845 million, reflecting 23%-28% growth, and EBITDA of $415 million to $440 million, indicating over 30% growth. Ongoing regulatory approvals for ENHANZE® products are anticipated to bolster future performance.
Halozyme Therapeutics (NASDAQ: HALO) announced it will release its fourth quarter and full year 2022 financial results on February 21, 2023, after trading closes. A conference call will follow at 4:30 p.m. ET, accessible via pre-registration. The call will also be webcast live on Halozyme's website.
Halozyme focuses on improving patient experiences and outcomes through its ENHANZE® technology, facilitating drug delivery and reducing treatment burdens. The company has impacted over 600,000 patients globally with its products, partnering with major pharmaceutical firms.
Halozyme Therapeutics (NASDAQ: HALO) announced the appointment of Barbara Duncan to its Board of Directors on February 6, 2023. Ms. Duncan has over 25 years of experience in the biopharmaceutical industry, having served as CFO at Intercept Pharmaceuticals and held key positions at DOV Pharmaceutical and Lehman Brothers. Dr. Helen Torley, President and CEO, expressed confidence that Ms. Duncan’s financial expertise would contribute to the company's growth. Halozyme is known for its ENHANZE® technology, which improves drug delivery, having impacted over 600,000 patients globally.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) plans to redeem all outstanding 1.25% convertible senior notes due 2024 on March 17, 2023. Holders can convert their notes at a rate of 42.0331 shares per $1,000 principal amount, equating to a conversion price of approximately $23.79 per share. Non-converted notes will be redeemed at 100% of their principal plus accrued interest. This action is part of the company's strategy to manage its debt effectively.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced robust financial guidance for 2023, projecting total revenues of $815 to $845 million, representing over 20% growth versus 2022. Recurring revenues from royalties are expected to exceed $445 million, marking a similar growth rate. The EBITDA is projected to rise by over 30%, reaching between $415 and $440 million. Non-GAAP diluted EPS guidance ranges from $2.50 to $2.65. The company anticipates two new commercial launches and significant growth in its ENHANZE pipeline.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have its president and CEO, Dr. Helen Torley, present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. The event will be accessible via a live audio webcast on the company's Investor Relations page, with replays available for 30 days. Halozyme is known for its innovative ENHANZE® technology, facilitating drug delivery for better patient outcomes and has impacted over 600,000 patients globally. The company also develops advanced drug-device combination products to enhance patient comfort and adherence.
Halozyme Therapeutics (NASDAQ: HALO) has announced participation in several upcoming investor conferences. Management, led by Dr. Helen Torley, will present at the J.P. Morgan Equity Opportunities Forum on November 15, 2022, in Miami, FL, and at the Piper Sandler Health Conference on November 30, 2022, in New York, NY, followed by the Evercore IS HealthCONx Conference on December 1, 2022, in a virtual format. Live webcasts of the events will be available on Halozyme's Investor Relations section.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported third quarter revenue of $209 million, up 80% year-over-year, with GAAP diluted EPS of $0.44 and non-GAAP diluted EPS of $0.74. Royalty revenue rose 70% year-over-year to $99.6 million. The company reiterated its 2022 revenue guidance of $655 million to $685 million, anticipating 48%-55% growth compared to 2021. Key advancements include regulatory submissions for ENHANZE® products. Cash and equivalents stood at $265.6 million as of September 30, 2022.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its third quarter 2022 financial and operating results on November 8, 2022, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss these results. Interested parties can register for the call here, and a live webcast will also be available on Halozyme's investor relations site. Halozyme, known for its ENHANZE® technology, aims to enhance patient experiences through innovative biopharmaceutical solutions.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced Dr. Helen Torley's participation at the 2022 Wells Fargo Healthcare Conference from September 7-9, 2022, in Boston, MA. Dr. Torley will present on September 8 at 5:35 a.m. PT / 8:35 a.m. ET, alongside hosting investor meetings. A live audio webcast of the presentation will be available on the Company’s Investor Relations section, with replays accessible for 90 days post-conference. Halozyme is renowned for its ENHANZE® technology, enhancing drug delivery and improving patient experiences.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
